← Eichor
Condition: Hepatic Encephalopathy Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hepatic Encephalopathy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Correlation Between Serum Albumin Level and Severity of Hepatic Encephalopathy in Patients With Chronic Liver Disease in
Phase N/A · 1 location(s) · Sohag University · NCT06953921Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
Phase 3 · 1 location(s) · Tanta University · NCT04161053Underdilated-stent Technique Improves Post-TIPS Encephalopathy
NA · 2 location(s) · The Second Affiliated Hospital of Chongqing Medical Universi · NCT07349654Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
Phase 4 · 1 location(s) · Asian Institute Of Medical Sciences · NCT07521332Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
NA · 2 location(s) · Mayo Clinic · NCT06425380The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)
Phase N/A · 1 location(s) · University of Malaya · NCT07418008RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
Phase 1/Phase 2 · 14 location(s) · Resolution Therapeutics Limited · NCT06823713VICIS - Vienna Cirrhosis Study
Phase N/A · 1 location(s) · Medical University of Vienna · NCT03267615Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Phase 4 · 6 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT04073290A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis
Phase 4 · 2 location(s) · Asian Institute of Gastroenterology, India · NCT06808074BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
Phase 4 · 1 location(s) · Post Graduate Institute of Medical Education and Research, C · NCT06538077Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
NA · 1 location(s) · General Hospital of Shenyang Military Region · NCT06483737Safety and Efficacy of Fecal Microbiota Transplantation
NA · 1 location(s) · Chinese University of Hong Kong · NCT04014413Faecal Microbiota Transplantation for Liver Cirrhosis
Phase 2/Phase 3 · 1 location(s) · University of Aarhus · NCT04932577Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
NA · 1 location(s) · The Cleveland Clinic · NCT04096014Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis
NA · 1 location(s) · Air Force Military Medical University, China · NCT07253389Affect of Melatonin on Sleep and Cognition in Cirrhosis
NA · 1 location(s) · Weill Medical College of Cornell University · NCT07046429Fecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS Surgery
EARLY_Phase 1 · 1 location(s) · Air Force Military Medical University, China · NCT07683936Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
Phase 2 · 1 location(s) · Hunter Holmes Mcguire Veteran Affairs Medical Center · NCT06052176Development of a Cognitive Tool for Rapid and Reliable Screening of Minimal Hepatic Encephalopathy: Pilot Study
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06619106A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
Phase 3 · 23 location(s) · King's College London · NCT06461208
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.